Posted by Michael Wonder on 09 Jan 2017
Medicare to cover infliximab biosimilar
6 January 2017 - The Centers for Medicare and Medicaid Services will pay for the biosimilar Inflectra (infliximab-dyyb) for Medicare enrollees.
The payment for Inflectra as a Medicare Part B-covered drug is 15% less than the wholesale acquisition cost of the original formulation of infliximab (Remicade), the company said in a press release.
Inflectra was approved by the FDA in April and began being shipped in November.
